98%
921
2 minutes
20
Background: Surgical treatment of complex giant pituitary adenomas (GPAs) presents significant challenges. The efficacy and safety of combining transsphenoidal and transcranial approaches for these tumors remain controversial. In this largest cohort of patients with complex GPAs, we compared the surgical outcomes between those undergoing a combined regimen and a non-combined regimen. We also examined the differences in risks of complications, costs, and logistics between the two groups, which might offer valuable information for the appropriate management of these patients.
Patients And Methods: This was a multicenter retrospective cohort study conducted at 13 neurosurgical centers. Consecutive patients who received a combined or non-combined regimen for complex GPAs were enrolled. The primary outcome was gross total resection, while secondary outcomes included complications, surgical duration, and relapse. A propensity score-based weighting method was used to account for differences between the groups.
Results: Out of 647 patients [298 (46.1%) women, mean age: 48.5 ± 14.0 years] with complex GPAs, 91 were in the combined group and 556 were in the noncombined group. Compared with the noncombined regimen, the combined regimen was associated with a higher probability of gross total resection [50.5% vs. 40.6%, odds ratio (OR): 2.18, 95% confidence interval (CI): 1.30-3.63, P = 0.003]. The proportion of patients with life-threatening complications was lower in the combined group than in the non-combined group (4.4% vs. 11.2%, OR: 0.25, 95% CI: 0.08-0.78, P = 0.017). No marked differences were found between the groups in terms of other surgical or endocrine-related complications. However, the combined regimen exhibited a longer average surgery duration of 1.3 h ( P < 0.001) and higher surgical costs of 22,000 CNY (~ 3,000 USD, P = 0.022) compared with the noncombined approach.
Conclusions: The combined regimen offered increased rates of total resection and decreased incidence of life-threatening complications, which might be recommended as the first-line choice for these patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254263 | PMC |
http://dx.doi.org/10.1097/JS9.0000000000001330 | DOI Listing |
JBJS Rev
September 2025
Joondalup Health Campus, Joondalup, Australia.
Background: Postoperative swelling is a common complication after total knee arthroplasty (TKA), associated with pain, limited mobility, and delayed recovery. This study aimed to systematically review the literature on interventions that reduce postoperative swelling, categorized into preoperative, intraoperative, and postoperative phases.
Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant search of PubMed, Medline, Embase, and Cochrane databases was performed for clinical studies evaluating interventions to reduce swelling after primary TKA.
Int J Audiol
September 2025
Department of Otolaryngology-Head & Neck Surgery, University of California San Francisco, San Francisco, California, USA.
Objective: To develop and pilot test a combined-learning intervention for Tanzanian primary healthcare workers on ear and hearing care (EHC), comprising five self-led smartphone-based modules and in-person workshops.
Design: The intervention was piloted with primary healthcare workers in Tanzania. Pre- and post-training surveys assessed knowledge, confidence, and attitudes towards EHC via Likert scales.
J Infect Dev Ctries
August 2025
Department of Emergency, Changhai Hospital, Naval Medical University, Shanghai, China.
Introduction: Nocardia spp. are Gram-positive, aerobic actinomycetes, which can cause pulmonary, primary cutaneous, and lymphocutaneous infections. However, severe pneumonia caused by Nocardia otitidiscaviarum has rare reported.
View Article and Find Full Text PDFCurr Opin Infect Dis
September 2025
Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Purpose Of Review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. This review summarizes current knowledge on the optimal use of SUL-DUR, whether administered alone or in combination with carbapenems, particularly imipenem.
Recent Findings: Data from registrational trial demonstrate that SUL-DUR is an effective and well tolerated treatment option for CRAB severe infections.
Adv Ther
September 2025
Sanofi, Gentilly, France.
Introduction: No head-to-head studies comparing the efficacy of avalglucosidase alfa (AVA) with cipaglucosidase alfa + miglustat (Cipa+mig) have been conducted in patients with late-onset Pompe disease (LOPD). Two indirect treatment comparisons (ITCs) were conducted to estimate the effects of AVA versus Cipa+mig.
Methods: ITCs were conducted using simulated treatment comparisons (STCs), adjusting for differences in prognostic factors and treatment effect modifiers.